Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maintenance study of obefazimod in moderate to severe ulcerative colitis
MOH_2023-06-13_012741Phase 3Active, not recruiting
- Sponsor
- Abivax
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of obefazimod in autoimmune colitis (3 arms), sponsored by Abivax. Primary endpoint: Clinical remission at week 44. Started Apr 2023; status: active, not recruiting.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2023-06-13_012741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-13_012741.